155 related articles for article (PubMed ID: 15146366)
21. Thyroid cancer in patients with acromegaly: a case-control study.
dos Santos MC; Nascimento GC; Nascimento AG; Carvalho VC; Lopes MH; Montenegro R; Montenegro R; Vilar L; Albano MF; Alves AR; Parente CV; dos Santos Faria M
Pituitary; 2013 Mar; 16(1):109-14. PubMed ID: 22527615
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of thyroid disease and thyroid malignancy in acromegalic patients.
Cankurtaran Y; Örük GG; Tozduman B
Minerva Endocrinol (Torino); 2023 Jun; 48(2):130-139. PubMed ID: 33988006
[TBL] [Abstract][Full Text] [Related]
23. Risk factors associated with thyroid nodular disease in acromegalic patients: A case-cohort study in a tertiary center.
Vargas-Ortega G; Romero-Gameros CA; Rendón-Macias ME; Balcázar-Hernández L; Sosa-Eroza E; Mercado M; de Los Monteros-Sánchez ALE; Pérez-Aguilar B; Paredes-Manjarrez C; Reyes-Olhagaray FB; Serrano-Ramírez DL; la Cruz EVM; González-Virla B
Growth Horm IGF Res; 2021; 60-61():101431. PubMed ID: 34740022
[TBL] [Abstract][Full Text] [Related]
24. The thyroid gland in acromegaly: an ultrasonographic study.
Cheung NW; Boyages SC
Clin Endocrinol (Oxf); 1997 May; 46(5):545-9. PubMed ID: 9231049
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of thyroid nodule growth.
Quadbeck B; Pruellage J; Roggenbuck U; Hirche H; Janssen OE; Mann K; Hoermann R
Exp Clin Endocrinol Diabetes; 2002 Oct; 110(7):348-54. PubMed ID: 12397534
[TBL] [Abstract][Full Text] [Related]
26. Increased incidence of euthyroid and hyperthyroid goiters independently of thyrotropin in patients with acromegaly.
Wüster C; Steger G; Schmelzle A; Gottswinter J; Minne HW; Ziegler R
Horm Metab Res; 1991 Mar; 23(3):131-4. PubMed ID: 1907592
[TBL] [Abstract][Full Text] [Related]
27. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
28. Thyroid lesions in patients with acromegaly - case-control study and update to the meta-analysis.
Woliński K; Stangierski A; Gurgul E; Bromińska B; Czarnywojtek A; Lodyga M; Ruchała M
Endokrynol Pol; 2017; 68(1):2-6. PubMed ID: 28255974
[TBL] [Abstract][Full Text] [Related]
29. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute.
Kurimoto M; Fukuda I; Hizuka N; Takano K
Endocr J; 2008 Mar; 55(1):67-71. PubMed ID: 18202526
[TBL] [Abstract][Full Text] [Related]
30. Growth hormone pulsatility in active and cured acromegalic subjects.
Semer M; Faria AC; Nery M; Salgado LR; Knoepfelmacher M; Wajchenberg BL; Liberman B
J Clin Endocrinol Metab; 1995 Dec; 80(12):3767-70. PubMed ID: 8530632
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the natural course of thyroid nodules in patients with acromegaly.
Dogansen SC; Salmaslioglu A; Yalin GY; Tanrikulu S; Yarman S
Pituitary; 2019 Feb; 22(1):29-36. PubMed ID: 30430336
[TBL] [Abstract][Full Text] [Related]
32. Increased thyroid cancer risk in acromegaly.
Dagdelen S; Cinar N; Erbas T
Pituitary; 2014 Aug; 17(4):299-306. PubMed ID: 23836362
[TBL] [Abstract][Full Text] [Related]
33. High prevalence of colonic polyps in patients with acromegaly. Influence of sex and age.
Terzolo M; Tappero G; Borretta G; Asnaghi G; Pia A; Reimondo G; Boccuzzi A; Cesario F; Rovero E; Paccotti P
Arch Intern Med; 1994 Jun; 154(11):1272-6. PubMed ID: 8203994
[TBL] [Abstract][Full Text] [Related]
34. Thyroid volume and serum thyroglobulin levels in patients with acromegaly: correlation with plasma insulin-like growth factor I levels.
Miyakawa M; Saji M; Tsushima T; Wakai K; Shizume K
J Clin Endocrinol Metab; 1988 Nov; 67(5):973-8. PubMed ID: 3053751
[TBL] [Abstract][Full Text] [Related]
35. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
36. [Acromegaly and thyroid disease: prevalence of thyroid cancer].
Marchisotti FG; Umeda LM; Zach PL; Saldanha MD; First OS; Liberman B
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):843-9. PubMed ID: 16444369
[TBL] [Abstract][Full Text] [Related]
37. Is there an association between acromegaly and thyroid carcinoma? A critical review of the literature.
Siegel G; Tomer Y
Endocr Res; 2005; 31(1):51-8. PubMed ID: 16238191
[TBL] [Abstract][Full Text] [Related]
38. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
Caron P; Morange-Ramos I; Cogne M; Jaquet P
J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
[TBL] [Abstract][Full Text] [Related]
39. Conductive hearing loss in patients with active acromegaly.
Babic BB; Petakov MS; Djukic VB; Ognjanovic SI; Arsovic NA; Isailovic TV; Milovanovic JD; Macut D; Damjanovic SS
Otol Neurotol; 2006 Sep; 27(6):865-70. PubMed ID: 16936573
[TBL] [Abstract][Full Text] [Related]
40. Prostatic disorders in acromegalic patients experience of a Brazilian center.
Corrêa LL; Balarini Lima GA; Cavallieri SA; Miranda LC; Gadelha MR
Int Braz J Urol; 2013; 39(3):393-401. PubMed ID: 23849571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
